Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Wells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.
Shares of Myriad Genetics closed at $29.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Downgrades PennTex Midstream Partners, LP (PTXP) to Hold
- Guggenheim Downgrades Core Laboratories (CLB) to Neutral
- BTIG Downgrades Essent Group (ESNT) to Neutral
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesWells Fargo
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!